Radiation Retinopathy Clinical Trial
Official title:
High Dose (2.0mg) Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy
This study investigates the use of a high dose anti-VEGF agent for the treatment of radiation retinopathy in those patients who have recalcitrant disease.
This study is an open-label, Phase I study of intravitreally administered ranibizumab in subjects with radiation retinopathy. This is a single center, non-randomized, active treatment study involving 10 consecutive patients. This study will evaluate the safety and tolerability of a high dose (2.0 mg) intravitreal ranibizumab and its effect on regression of radiation retinopathy and mean change in visual acuity. ;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02222610 -
Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.
|
Phase 2 | |
Active, not recruiting |
NCT04120311 -
Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole
|
Phase 1 | |
Completed |
NCT00750399 -
Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma
|
Phase 1 | |
Recruiting |
NCT05844982 -
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
|
Phase 3 | |
Completed |
NCT01579760 -
Intravitreal Aflibercept Injection for Radiation Retinopathy
|
Phase 1 | |
Active, not recruiting |
NCT04120636 -
Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole
|
Phase 1 | |
Active, not recruiting |
NCT03085784 -
Intravitreal Aflibercept Injection for Radiation Retinopathy Trial
|
Phase 2 | |
Withdrawn |
NCT03238157 -
Steroids for Early Treatment of Radiation Retinopathy
|
Phase 2/Phase 3 | |
Terminated |
NCT01471054 -
Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma
|
Phase 2 | |
Active, not recruiting |
NCT00540930 -
Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy
|
Phase 4 |